{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-062005","form_type":"8-K","ticker":"ACHV","cik":"0000949858","company_name":"ACHIEVE LIFE SCIENCES, INC.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.487118+00:00","generated_at":"2026-06-08T08:27:22.067305+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Achieve Life Sciences reports Q3 2023 net loss $7.1M; cash $20M; advances cytisinicline trials","bullets":["Cash and restricted cash $20.0M as of Sep 30, 2023; net loss $7.1M in Q3 2023.","ORCA-2 Phase 3 smoking cessation results published in JAMA; cytisinicline showed significant efficacy.","Completed dosing of three NDA-supportive studies (QT, PK in smokers, renal impairment); data due early 2024.","Phase 2 ORCA-V1 results presented: 2.6-fold increase in vaping cessation odds vs placebo.","Shares outstanding: 21,165,760 as of Nov 9, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-062005","json":"https://secwatch.observer/filing/0000950170-23-062005.json","markdown":"https://secwatch.observer/filing/0000950170-23-062005.md","text":"https://secwatch.observer/filing/0000950170-23-062005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/949858/000095017023062005/0000950170-23-062005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/949858/000095017023062005/achv-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T08:27:22.067305+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d06f021111a9df010014bd4b167ad50d1e48213d","claim":"ACHIEVE LIFE SCIENCES, INC. reported third quarter 2023 results: net income Total net loss for the three and nine months ended September 30, 2023 was $7.1 million and $24.3 million, respectively..","evidence_excerpt":"Total net loss for the three and nine months ended September 30, 2023 was $7.1 million and $24.3 million, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/949858/000095017023062005/0000950170-23-062005-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter 2023"},{"label":"Net income","value":"Total net loss for the three and nine months ended September 30, 2023 was $7.1 million and $24.3 million, respectively."},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}